Pharmaceutical News and Articles

Risk of Obesity-Related Cancer Similar for GLP-1 Receptor Agonists and Bariatric Surgery

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being treated for diabetes and obesity, accor

Improvements In Prostate Cancer Tracking Help Men Stay In Active Surveillance

THURSDAY, May 15, 2025 Men in watchful waiting mode for their low-risk prostate cancer are staying healthier longer thanks to advanced imaging and treatments de

Broken Heart Syndrome Remains A Killer, Especially For Men

THURSDAY, May 15, 2025 Broken heart syndrome sounds like a romantic, fairy-tale notion the idea that suffering a devastating loss that can cause one s heart to

Smartphones Aid Recovery From Broken Leg, Hip

THURSDAY, May 15, 2025 A person s smartphone can show how well they ll recover from a broken leg or hip, a new study says. Smartphone data showing a person s mo

Alzheimer’s Drug Can Be Safely Administered In Memory Clinics, Study Says

THURSDAY, May 15, 2025 The 2023 approval of the first drug shown to slow the progression of Alzheimer s disease came with no small amount of concern from skepti

Study Finds No Link Between COVID Vaccine And Miscarriage Risk

THURSDAY, May 15, 2025 There s no link between the COVID-19 vaccine and miscarriage, a new study says. COVID poses significant risks to pregnant women, includin

FDA Approves Merck’s Welireg (belzutifan) for the Treatment of Adults and Pediatric Patients 12 Years and Older With Locally Advanced, Unresectable, or Metastatic Pheochromocytoma or Paraganglioma (PPGL)

The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1

OSAKA, Japan and CAMBRIDGE, Massachusetts, May 14, 2025 Takeda (TSE 4502 NYSE TAK) today announced that the New England Journal of Medicine published data from

FDA Extends PDUFA Date of Biohaven's Troriluzole NDA for Rare Disease Spinocerebellar Ataxia

Pathological Fatigue Common Up to 12 Months After TIA

Pathological fatigue is common up to 12 months after a diagnosis of transient ischemic attack (TIA), according to a study published online May 14 in Neurology.